2 Reasons to Like RKLB and 1 to Stay Skeptical

Rocket Lab trades at $73.84 and has rallied 577% since April 2021, far outpacing the S&P 500’s 66.4% gain. The article highlights strong five-year revenue CAGR of 76.5% and analyst expectations for another 41.7% revenue increase over the next 12 months, but flags heavy cash burn with an average free cash flow margin of -53.8%. Overall, the piece is constructive on fundamentals but cautious on valuation, citing a 48.5x forward price-to-sales multiple.

Analysis

RKLB is getting the kind of multiple expansion that usually precedes a more volatile tape than the headline momentum suggests. At ~48x forward sales, the equity is no longer priced like an early-stage aerospace option; it is being valued like a durable platform with a high probability of converting revenue growth into eventual operating leverage. That creates a fragile setup: any evidence that growth is merely “good” rather than “exceptional” can compress the multiple faster than fundamentals deteriorate.

The key second-order issue is that Rocket Lab’s business is not just a launch story; it is a capital-intensity and execution story. Heavy reinvestment can sustain top-line growth for years, but the market will eventually demand proof that incremental revenue is not being bought at an ever-rising cash cost. If margins or free cash flow inflect slower than consensus expects over the next 2-4 quarters, the stock can de-rate even if revenue keeps compounding.

The broader winner set includes suppliers and adjacent small-sat ecosystem names that benefit from rising mission cadence and investor attention, but the more interesting trade is against overstretched expectation risk. The market is implicitly assuming that the company can keep converting technical credibility into commercial scale without a reset in cadence, launch reliability, or customer concentration. Any hiccup there would likely hit the stock harder than peers because positioning is already momentum-heavy.

Contrarian view: the consensus may be underestimating how much of the good news is already in the price. The setup is favorable for continued outperformance only if near-term prints reinforce that growth is accelerating into a path toward cash discipline; otherwise, this becomes a classic “great company, bad entry point” situation. In other words, the stock may still be structurally interesting, but tactically it is more attractive on pullbacks or after a volatility reset than after a run to this valuation band.

Key Decisions for Investors

• Avoid initiating a fresh outright long at current levels; wait for a 15-20% drawdown or a post-earnings volatility event before building exposure, because the current multiple leaves limited upside if growth merely meets expectations.
• If already long RKLB, collar the position into the next earnings window: sell upside calls against shares and finance downside puts to protect against a multiple compression event over the next 30-60 days.
• Pair trade: long a profitable aerospace/defense prime with visible free-cash-flow conversion, short RKLB for 1-2 quarters. The thesis is that the market will continue rewarding cash-generative defense exposure while punishing any “growth at any cost” disappointment.
• For higher-risk expression, buy RKLB Jan-2026 put spreads instead of naked puts. This targets the 2-3 quarter window where the market will test whether revenue growth is translating into operating leverage; risk is capped if the stock stays momentum-driven.
• If buying exposure, scale in only after evidence of free-cash-flow inflection. The right catalyst is not another strong revenue print alone, but a quarter showing improving cash burn per dollar of incremental revenue.